Table 3 Selected ongoing clinical trials of inotuzumab ozogamicin for patients with newly diagnosed B-cell ALL
Trial | Age (years) | ALL subtypes | Primary endpoint | Data presented or published | Trial identifier |
|---|---|---|---|---|---|
INO induction followed by low-intensity chemotherapy (INITIAL-1) | 56–74 | Ph-negative | Event-free survival | Yes [36] | NCT03460522 |
INO + dasatinib + dexamethasone | 18+ | Ph-positive | Complete remission with MMR | No | NCT04747912 |
INO + blinatumomab + hyper-CVAD | 14+ | Ph-negative | Relapse-free survival | Yes [40] | NCT02877303 |
INO + blinatumomab + mini-hyper-CVD | 60+ | Ph-negative or Ph-positive | Progression-free survival | Yes [33] | NCT01371630 |
INO + mini-hyper-CVD versus dose-adjusted hyper-CVAD (Alliance A042001) | 50+ | Ph-negative | Event-free survival | No | NCT05303792 |
INO induction followed by blinatumomab (Alliance 041703) | 60+ | Ph-negative | Event-free survival | Yes [35] | NCT03739814 |
INO + low-intensity chemotherapy (EWALL-INO) | 55+ | Ph-negative | Overall survival | Yes [37] | NCT03249870 |